INDBInternet News Database 2.5 Updated 1 min ago · 296 sources Show or hide images Light or dark

CHMP Endorses New Add-On Option for Active SLE

Save Like Comments Compare coverage

Summary

Obinutuzumab could become a new add-on option for autoantibody-positive SLE after a randomized study showed significantly higher response rates vs placebo. Medscape News Europe

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    CHMP Endorses New Add-On Option for Active SLE

    Obinutuzumab could become a new add-on option for autoantibody-positive SLE after a randomized study showed significantly higher response rates vs placebo. Medscape News Europe

Comments

Comments need JavaScript.